Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.
Patients who have signed informed consent for treatment.
Age <18 years
Patients with other types of cancer/lymphoma
Patients not eligible for the Mosunetuzumab compassionate use program
Andrés José Maria Ferreri
Lead sponsor
IRCCS San Raffaele
Sponsor institution